Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07629440 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
A Phase 3 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 3,230
- Enrollment target
NCT07629440: Recruiting Phase 3 study, sponsored by Pfizer.
NCT07629440 is a Phase 3 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 3,230 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (318% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07629440, a Phase 3 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 3,230 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. It will also assess how the new vaccine works in comparison to the one that is currently in use when given with other childhood vaccines. To measure how the new pneumococcal vaccine compares to the current one, blood samples will be used to measure the body's ability to create proteins to fight those germs. This new vaccine can possibly provide additional protection against germs that cause pneumococcal disease that are not included in the vaccines that are currently given to infants. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae. There are three groups in this study. All participants will be assigned to one of the three groups. This study is seeking participants who are: * infants who are 2 months of age in Group 1; * infants who are 2 to 6 months of age in Groups 2 and 3; and * said to be healthy by the study doctor About 3000 infants will be assigned to Group 1. The infants in this group will have a 1 in 2 chance (50%) of receiving either PG4 (new vaccine) or 20vPnC (currently in use) into the left thigh muscle at 2, 4, 6, and 12 to 15 months of age. About 140 infants from outside the United States will be assigned to Group 2. The infants in this group will have a 1 in 2 chance (50%) of receiving either PG4 or 20vPnC into the left thigh muscle at 2 to 6, 3 to 8, 4 to 10, and 12 to 15 months of age. About 90 infants from outside the United States will be assigned to Group 3. The infants in Group 3 will have a 1 in 3 chance (33%) of receiving eit
Primary Outcome
Prompted local reactions after each dose
Interventions
- BIOLOGICAL PG4
- BIOLOGICAL 20-valent pneumococcal conjugate vaccine (20vPnC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,230 participants |
| Start Date | 2026-05-29 |
| Est. Completion | 2029-06-05 |
| Phase | Phase 3 |
What NCT07629440 shows while recruiting
NCT07629440 is an interventional study that assigns participants to a tested intervention. Its 3,230 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (318% higher).
The record links to 0 conditions, and to 2 interventions - of which PG4 is the first listed.
NCT07629440 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07629440 about?
NCT07629440 is a clinical study titled "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.". The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumoco...
What is the current status of trial NCT07629440?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 3,230 participants. The study started on 2026-05-29. Estimated completion is 2029-06-05.
What interventions are being tested in trial NCT07629440?
The interventions under investigation include: PG4 (BIOLOGICAL), 20-valent pneumococcal conjugate vaccine (20vPnC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07629440?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07629440's enrollment target sits among peer trials
3,230 73rd of 2000 higher than 1,928 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06587529 · 3,218 participants · NA
Rigorous Evaluation of the READY to Stand Curriculum to Prevent the Commercial Sexual Exploitation of Children
- NCT06953375 · 3,250 participants · NA
Implementation of Neuromuscular Electrical Stimulation After Total Knee Arthroplasty
- NCT06760507 · 3,209 participants · NA
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
- NCT02043457 · 3,200 participants
Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI